Celldex announces new barzolvolimab data at EADV congress

Celldex (CLDX) announced new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E levels in patients with chronic spontaneous urticaria, an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data were presented in an oral e-poster presentation at the EADV Congress 2025. Barzolvolimab demonstrated rapid and sustained efficacy in patients with CSU with both low and normal/high IgE levels. Similar improvement in weekly urticaria activity scores were observed across both IgE low and IgE normal/high subgroups at Weeks 12 and 52. Similar rates of well-controlled disease and complete disease control were also observed across both IgE normal/high and IgE low subgroups at Weeks 12 and 52. Similar rates of well-controlled disease and complete disease control were also observed across both IgE normal/high and IgE low subgroups at Weeks 12 and 52. Data reinforce that mast cells are important drivers of CSU regardless of the underlying endotype and are consistent with the novel mechanism of action of barzolvolimab.